Phase II Trial of Investigational Agents to Modulate Intermediate Endpoint Biomarkers, Including Pulmonary Nodules, in Former and Current Smokers
Latest Information Update: 29 May 2025
At a glance
- Drugs Curcumin (Primary) ; Omega-3-acid ethyl esters (Primary)
- Indications Lung cancer
- Focus Therapeutic Use
Most Recent Events
- 23 May 2025 Planned End Date changed from 1 Aug 2025 to 1 May 2026.
- 23 May 2025 Planned primary completion date changed from 1 Aug 2025 to 25 May 2025.
- 23 May 2025 Status changed from recruiting to active, no longer recruiting.